摘要
目的 研究安徽地区汉族人群肿瘤患者UGT1A1*6基因多态性分布情况。方法 选取来自安徽省不同区域222例汉族肿瘤患者血液样本,采用原位杂交荧光染色分析技术检测患者UGT1A1*6基因型。结果 222例汉族肿瘤患者UGT1A1*6基因型具体分布情况为:UGT1A1*6野生型(GG)159例次,占总例次71.62%;突变杂合型(GA)52例次,占总例次23.42%;突变纯合型(AA)11例次,占总例次4.96%。UGT1A1*6突变率为16.67%,且在食道癌患者中该基因突变率为43.75%,在马鞍山及滁州地区患者中基因突变率分别为40.01%和34.62%,均明显高于其他部位肿瘤及地区患者水平(P<0.05)。结论 安徽地区汉族人群肿瘤患者UGT1A1*6突变频率较高,通过UGT1A1*6基因分型,可以预测伊立替康不良反应发生风险,为实施伊立替康个体化治疗提供用药参考。
Aim To investigate the gene frequency of UGT1 A1* 6 in cancer patients in Anhui Han population. Methods The 222 cases of blood samples ofHan cancer patients were collected from different regions of Anhui province,and the UGT1 A1 * 6 genotypes were detected by in situ hybridization fluorescencestaining. Results Patients with a UGT1 A1 * 6 wild type(GG) accounted for(159 cases,71. 62%),which were higher than those of heterozygous mutations(GA,52 cases,23. 42%) and of homozygous mutations(AA,11 cases,4. 96%) of the total cases. The mutation rate of UGT1 A1* 6 was 16. 67%,and particularly in patients with esophageal cancer it was43. 75%. The rates of mutation in the patients in Ma 'anshan and Chuzhou were 40. 01% and 34. 62%,respectively,both significantly higher than those of othertumors and regions. Conclusions Cancer patients in Anhui Han population have a high mutant frequency of UGT1 A1* 6. The UGT1 A1 * 6 genotyping can indirectly predict the risk of irinotecan's adverse reaction,which obviously enhances the potentially individualized treatment of irinotecan.
作者
栾家杰
刘俊
汪琳
朱艳虹
周德喜
左坚
徐振宇
LUAN Jia-jie;LIU Jun;WANG Lin;ZHU Yan-hong;ZHOU De-xi;ZUO Jian;XU Zhen-yu(Dept of Pharmacy,Yijishan Hospital of Wannan Medical College;Dept of Pharmacy Administration,Wannan Medical College, Wuhu, Anhui 241001, China)
出处
《中国药理学通报》
CAS
CSCD
北大核心
2018年第6期857-862,共6页
Chinese Pharmacological Bulletin
基金
国家自然科学基金资助项目(No 81602240)
安徽省科技攻关项目(No 1604a0802097)